Literature DB >> 28980026

[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].

D C Richter1, A Heininger2, T Brenner3, M Hochreiter3, M Bernhard4, J Briegel5, S Dubler3, B Grabein6, A Hecker7, W A Krüger8, K Mayer9, M W Pletz10, D Störzinger9, N Pinder9, T Hoppe-Tichy2, S Weiterer3, S Zimmermann2, A Brinkmann11, M A Weigand3, Christoph Lichtenstern3.   

Abstract

The mortality of patients with sepsis and septic shock is still unacceptably high. An effective antibiotic treatment within 1 h of recognition of sepsis is an important target of sepsis treatment. Delays lead to an increase in mortality; therefore, structured treatment concepts form a rational foundation, taking relevant diagnostic and treatment steps into consideration. In addition to the assumed focus and individual risks of each patient, local resistance patterns and specific problem pathogens must be taken into account for selection of anti-infection treatment. Many pathophysiological alterations influence the pharmacokinetics of antibiotics during sepsis. The principle of standard dosing should be abandoned and replaced by an individual treatment approach with stronger weighting of the pharmacokinetics/pharmacodynamics (PK/PD) index of the substance groups. Although this is not yet the clinical standard, prolonged (or continuous) infusion of beta-lactam antibiotics and therapeutic drug monitoring (TDM) can help to achieve defined PK targets. Prolonged infusion is sufficient without TDM but for continuous infusion TDM is basically necessary. A further argument for individual PK/PD-oriented antibiotic approaches is the increasing number of infections due to multidrug resistant pathogens (MDR) in the intensive care unit. For effective treatment antibiotic stewardship teams (ABS team) are becoming more established. Interdisciplinary cooperation of the ABS team with infectiologists, microbiologists and clinical pharmacists leads not only to a rational administration of antibiotics but also has a positive influence on the outcome. The gold standards for pathogen detection are still culture-based detection and microbiological resistance testing for the various antibiotic groups. Despite the rapid investigation time, novel polymerase chain reaction (PCR)-based procedures for pathogen identification and resistance determination, are currently only an adjunct to routine sepsis diagnostics due to the limited number of studies, high costs and limited availability. In complicated septic courses with multiple anti-infective treatment or recurrent sepsis, PCR-based procedures can be used in addition to therapy monitoring and diagnostics. Novel antibiotics represent potent alternatives in the treatment of MDR infections. Due to the often defined spectrum of pathogens and the practically absent resistance, they are suitable for targeted treatment of severe MDR infections (therapy escalation).

Entities:  

Keywords:  Drug resistance, multiple, bacterial; Lactams; Patient care bundles; Prolonged and continuous β‑lactam infusion; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2017        PMID: 28980026     DOI: 10.1007/s00101-017-0363-8

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  212 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?

Authors:  Federico Perez; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

Review 3.  Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.

Authors:  John G Muscedere; Andrew Day; Daren K Heyland
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

4.  Economic impact of ventilator-associated pneumonia in a large matched cohort.

Authors:  Marin H Kollef; Cindy W Hamilton; Frank R Ernst
Journal:  Infect Control Hosp Epidemiol       Date:  2012-01-17       Impact factor: 3.254

Review 5.  Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?

Authors:  Angela Huttner; Stephan Harbarth; William W Hope; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2015-07-17       Impact factor: 5.790

Review 6.  [Not Available].

Authors:  Christine Geffers; Friederike Maechler; Michael Behnke; Petra Gastmeier
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2016-03-07       Impact factor: 0.698

7.  Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU.

Authors:  Mariano Esperatti; Miquel Ferrer; Valeria Giunta; Otavio Tavares Ranzani; Lina Maria Saucedo; Gianluigi Li Bassi; Francesco Blasi; Jordi Rello; Michael S Niederman; Antoni Torres
Journal:  Crit Care Med       Date:  2013-09       Impact factor: 7.598

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

9.  Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Sara E Cosgrove; George Sakoulas; Eli N Perencevich
Journal:  BMC Infect Dis       Date:  2011-10-19       Impact factor: 3.090

10.  In silico serine β-lactamases analysis reveals a huge potential resistome in environmental and pathogenic species.

Authors:  Christian Brandt; Sascha D Braun; Claudia Stein; Peter Slickers; Ralf Ehricht; Mathias W Pletz; Oliwia Makarewicz
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

View more
  8 in total

1.  [Intensive care studies from 2017/2018].

Authors:  C J Reuß; M Bernhard; C Beynon; A Hecker; C Jungk; C Nusshag; M A Weigand; D Michalski; T Brenner
Journal:  Anaesthesist       Date:  2018-09       Impact factor: 1.041

Review 2.  [Adequate anti-infective treatment : Importance of individual dosing and application].

Authors:  A Brinkmann; A C Röhr; A Köberer; T Fuchs; W A Krüger; C König; D Richter; M A Weigand; O R Frey
Journal:  Anaesthesist       Date:  2018-06       Impact factor: 1.041

3.  Sustainable implementation of antibiotic stewardship on a surgical intensive care unit evaluated over a 10-year period.

Authors:  Stefan Schröder; Marie-Kathrin Klein; Bernhard Heising; Sebastian W Lemmen
Journal:  Infection       Date:  2019-11-13       Impact factor: 3.553

4.  Antimicrobial susceptibility testing of pathogens isolated from blood culture: a performance comparison of Accelerate Pheno™ and VITEK® 2 systems with the broth microdilution method.

Authors:  Giulia De Angelis; Brunella Posteraro; Giulia Menchinelli; Flora Marzia Liotti; Teresa Spanu; Maurizio Sanguinetti
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

5.  Protective Effects of Live Combined B. subtilis and E. faecium in Polymicrobial Sepsis Through Modulating Activation and Transformation of Macrophages and Mast Cells.

Authors:  Lisha Guo; Mei Meng; Yaping Wei; Feixue Lin; Ying Jiang; Xianzhen Cui; Guirong Wang; Chunting Wang; Xiaosun Guo
Journal:  Front Pharmacol       Date:  2019-01-21       Impact factor: 5.810

6.  The Clinical Diagnostic Values of SAA, PCT, CRP, and IL-6 in Children with Bacterial, Viral, or Co-Infections.

Authors:  Shunxin Zhu; Caixiu Zeng; Yan Zou; Yanjiao Hu; Canfang Tang; Chunmei Liu
Journal:  Int J Gen Med       Date:  2021-10-24

Review 7.  [Sepsis in out-of-hospital emergency medicine].

Authors:  Manuel Obermaier; Markus A Weigand; Erik Popp; Florian Uhle
Journal:  Notf Rett Med       Date:  2021-11-17       Impact factor: 0.892

Review 8.  The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review.

Authors:  Alessandro Lazzaro; Gabriella De Girolamo; Valeria Filippi; Giuseppe Pietro Innocenti; Letizia Santinelli; Giancarlo Ceccarelli; Enrico Maria Trecarichi; Carlo Torti; Claudio Maria Mastroianni; Gabriella d'Ettorre; Alessandro Russo
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.